Synergy Pharmaceuticals (SGYP) Receives Price Target

Synergy Pharmaceuticals (SGYP) : 2 Wall Street analysts covering Synergy Pharmaceuticals (SGYP) believe that the average level the stock could reach for the short term is $10.75. The maximum price target given is $15 and the minimum target for short term is around $7, hence the standard deviation is calculated at $6.01.

Synergy Pharmaceuticals (SGYP) : 2 analysts are covering Synergy Pharmaceuticals (SGYP) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.


Synergy Pharmaceuticals (NASDAQ:SGYP): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.70 and $4.64 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.77. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.76, notching a gain of 0.63% for the day. The total traded volume was 1,295,267 . The stock had closed at $4.73 on the previous day.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.